Phio Pharmaceuticals Corp.
PHIO Nasdaq
SEC CIK 1533040
Follow Phio Pharmaceuticals Corp.
Weekly email: filings, results
Net income
−$4.2M
−73.9% vs same quarter last year
EPS, diluted
−$0.36
+18.2% vs same quarter last year
Operating cash flow
−$2.3M
−9.4% vs same quarter last year
Operating income
−$4.3M
−70.4% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | - | −$8.7M |
| FY24 | - | −$7.2M |
| FY23 | - | −$10.8M |
| FY22 | - | −$11.5M |
| FY21 | - | −$13.3M |
| FY20 | $0 | −$8.8M |
| FY19 | $21K | −$8.9M |
| FY18 | $138K | −$7.4M |
| FY17 | $15K | −$12.5M |
| FY16 | $19K | −$9M |
| FY15 | $34K | −$10.2M |
| FY14 | - | −$8.8M |
| FY13 | $399K | −$20.9M |
| FY12 | $97K | −$12.9M |
| FY11 | - | −$2.5M |
- Operating margin
- Net margin
Show the numbers
| Year | Operating margin | Net margin |
|---|---|---|
| FY25 | - | - |
| FY24 | - | - |
| FY23 | - | - |
| FY22 | - | - |
| FY21 | - | - |
| FY20 | - | - |
| FY19 | −42795.2% | −42419% |
| FY18 | −5336.2% | −5333.3% |
| FY17 | −93746.7% | −83013.3% |
| FY16 | −47447.4% | −47336.8% |
| FY15 | −30108.8% | −30067.6% |
| FY14 | - | - |
| FY13 | −5250.4% | −5244.4% |
| FY12 | −13376.3% | −13278.4% |
| FY11 | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$8M |
| FY24 | −$7.1M |
| FY23 | −$10.8M |
| FY22 | −$12.3M |
| FY21 | −$11.9M |
| FY20 | −$8.8M |
| FY19 | −$8.7M |
| FY18 | −$7.5M |
| FY17 | −$9.7M |
| FY16 | −$7.8M |
| FY15 | −$7.4M |
| FY14 | −$7.9M |
| FY13 | −$6.4M |
| FY12 | −$5.1M |
| FY11 | - |
- Phio Pharmaceuticals Corp.
- Healthcare median
Show the numbers
| Year | Phio Pharmaceuticals Corp. | Healthcare median |
|---|---|---|
| FY25 | - | −30.6% |
| FY24 | - | −47% |
| FY23 | - | −58% |
| FY22 | - | −80.4% |
| FY21 | - | −71.8% |
| FY20 | - | −62.2% |
| FY19 | −42419% | −46.2% |
| FY18 | −5333.3% | −49.6% |
| FY17 | −83013.3% | −45.9% |
| FY16 | −47336.8% | −36% |
| FY15 | −30067.6% | −37.8% |
| FY14 | - | −35.5% |
| FY13 | −5244.4% | −37.1% |
| FY12 | −13278.4% | −29.1% |
| FY11 | - | −27.9% |